CTGF has been identified as a glucose-induced modulator of cell sensitivity to tamoxifen and the CTGF silencing induced a significant increase in tamoxifen sensitivity of BC cells grown in hyperglicemia, at levels like those obtained for cells cultured in normal levels of glycemia. Here, CCN2 is linked to breast cancer.